Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Research Areas > Cancer > Liver Cancer

Liver Cancer

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC10372 Amcasertib(BBI503) Featured
Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.
More description
DC5065 Golvatinib (E7050) Featured
E-7050 is hepatocyte growth factor receptors (HGFR).
More description
DC10440 Namodenoson (CF-102) Featured
CF-102(2-Cl-IB-MECA) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively. target: A3 adenosine receptor agonist;
More description
DC11163 AST-3424 Featured
AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.
More description
DC7065 Tivantinib (ARQ 197) Featured
Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.
More description
DC10033 H3B-6527 Featured
H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
More description
DC10128 FGF401( Roblitinib) Featured
FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.
More description
DC10092 BLU554(Fisogatinib) Featured
BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.
More description
DC5032 AZD1480 Featured
AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2.
More description
DC4105 Linsitinib(OSI-906) Featured
OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively.
More description
DC7808 Refametinib (BAY86-9766) Featured
Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.
More description
DC10559 Derazantinib (ARQ 087) Featured
Derazantinib (Derazantinib) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
More description
DC2019 Brivanib (bms-540215) Featured
Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.
More description
DC11087 TRX-818 sodium
TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.
More description
DC11812 SF-1126
SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.
More description
DC7261 Resminostat hydrochloride (4SC-201)
Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM.
More description
DC11086 Foslinanib
Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.
More description
DCAPI1441 Seocalcitol
EB1089 is an analog of 1,25 dihydroxyvitamin D which acts as a vitamin D receptor (VDR). EB1089 is noted to reverse hypercalcemia and is a potent inhibitor of PTH-rP (parathyroid hormone-related peptide, PTHRP) in vitro. In studies utilizing a squamous ca
More description
DC11295 AZD-4573
AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X